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Background: An association between vitamin B12 levels and depressive symptoms (DS) has been reported in
several epidemiological studies. The purpose of this study was to evaluate vitamin B12 levels in population-based
samples with melancholic or non-melancholic DS as the relationship between vitamin B12 levels and different
subtypes of DS has not been evaluated in previous studies.
Methods: Subjects without previously known type 2 diabetes, aged 45–74 years were randomly selected from the
National Population Register as a part of the Finnish diabetes prevention programme (FIN-D2D). The study
population (N = 2806, participation rate 62%) consisted of 1328 men and 1478 women. The health examinations
were carried out between October and December 2007 according to the WHO MONICA protocol. The assessment
of DS was based on the Beck Depression Inventory (BDI, cut-off ≥10 points). A DSM-IV- criteria based summary
score of melancholic items in the BDI was used in dividing the participants with DS (N = 429) into melancholic
(N = 138) and non-melancholic DS (N = 291) subgroups. In the statistical analysis we used chi-squared test, t-test,
permutation test, analysis of covariance, multivariate logistic regression analysis and multinomial regression model.
Results: The mean vitamin B12 level was 331±176 pmol/L in those without DS while the subjects with non-
melancholic DS had a mean vitamin B12 level of 324 ± 135 pmol/L, and those with melancholic DS had the lowest
mean vitamin B12 level of 292±112 pmol/L (p < 0.001 after adjusted for age, sex, use of antidepressive medication and
chronic diseases sum index). The adjusted difference of vitamin B12 levels between the non-melancholic and the
melancholic group was 33 pmol/L (95%CI 8 to 57, p = 0.008). Melancholic DS and vitamin B12 levels showed an
independent linearly inverse association. The relative risk ratio (RRR) for melancholic DS was 2.75 (95%CI 1.66 to 4.56) in
the lowest vitamin B12 level tertile versus the highest (p for linearity <0.001) when those without DS formed the
reference group. The RRR in the non-melancholic subgroup was nonsignificant.
Conclusions: The vitamin B12 level was associated with melancholic DS but not with non-melancholic DS.
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Depression is a global public health problem particularly
in developed countries. Recently, the World Health
Organization estimated that unipolar depressive disorder
remains one of the leading causes of total disability ad-
justed life years (DALY’s ) worldwide [1]. It accounts for
8% of total DALY’s in the Americas and 6% in Europe
[2]. Overall, the 12-month and lifetime prevalence rates
of depression are approximately 12% and 24% among
U.S. men and women, respectively [3].
A wide array of etiological hypotheses has been sug-
gested to underlie depression. Of the biological hypoth-
eses, the monoamine hypothesis proposes an important
etiological role for serotoninergic or noradrenergic dys-
function in depression [4]. Besides folate, vitamin B12 is
involved in single-carbon transfer reactions needed for
the production of serotonin and other monoamine neu-
rotransmitters [5]. Vitamin B12 deficiency may also re-
sult in the accumulation of homocysteine, which has
been suggested to lead to exito-toxic reactions and
may enhance depression [6,7]. Homocysteine can be
remethylated to methionine, which requires vitamin B12
[8]. Methionine is the immediate precursor of S-
adenosylmethionine (SAM), the methyl donor of numer-
ous methylation reactions in the brain, many of which
are directly involved in the synthesis and metabolism of
dopamine, norepinephrine and serotonin [9]. These find-
ings form a plausible link between vitamin B12 and
mood, and may also indicate that the association be-
tween depression and vitamin B12 could be mediated
through monoamine synthesis.
In clinical studies, lower vitamin B12 levels have been
found to be associated with severe depression [10,11].
Low serum vitamin B12 levels are also detected in
approximately 20% of psychiatric patients [12]. On the
other hand, high vitamin B12 levels were associated
with a good treatment outcome in patients with major
depressive disorders in a clinical setting [13]. However,
a small randomised trial found no improvement in de-
pression after the administration of vitamin B12 as an
adjuvant [14].
The three cross-sectional studies and one prospective
population-based study that have reported a connection
between vitamin B12 levels and DS or depressive disor-
ders were conducted on older adults [15-18]. In the
Women’s Health and Aging Study B12 deficiency was
associated with a two-fold increased risk of severe
depression [15]. The Rotterdam Study found that B12 de-
ficiency was independently associated with depres-
sive disorder among older adults [16]. A study among
Chinese older adults also found a correlation between
deficient levels of vitamin B12 and greater risk of DS
[18]. The only existing community-based prospective
study reported that lower levels of vitamin B12 atbaseline were associated with a higher risk of incident of
depression on 2–3 year follow-up among older Korean
people [17]. However, previous results have been some-
what inconsistent, since some studies, mainly conducted
in younger populations, have found no association be-
tween vitamin B12 levels and DS or depressive disorders
[19-23].
Methods
Study population and the setting of the study
The Finnish type 2 diabetes (FIN-D2D) survey is the im-
plementation project of a national programme for the
prevention of type 2 diabetes covering a population of
1.5 million during the years 2003–2008 [24]. The spe-
cific aims were to improve the screening of people at
risk of diabetes and the detection of undiagnosed dia-
betes, as well as the prevention of diabetes among na-
tional population.
A random sample of 4500 subjects without previously
known type 2 diabetes, aged 45–74 years, stratified
according to gender and 10-year age groups (45–54, 55–
64 and 65–74 years), was selected from the National
Population Register of Finland in August 2007. The sam-
pling represented three separate geographical areas with
both urban and rural populations. The study participants
were invited by mail to a health examination. The study
population (N = 2806, participation rate 62%) consisted
of 1328 men and 1478 women. The participants and the
nonparticipants (N = 1694) did not differ with regard to
age or gender distribution. The Ethical Committee of
the Hospital District of Helsinki and Uusimaa approved
the study protocol. All participants gave their written in-
formed consent prior to participation in the study.
Design of the study and measurements
Depressive symptoms
DS were assessed by using the Beck Depression Inven-
tory (BDI), which is a 21-item self-report questionnaire
consisting of symptoms and attitudes related to depres-
sion [25]. The items are summed in a total score with a
range from 0 to 63. The cut-off point for DS was 10,
which has been reported to be a feasible instrument for
depression screening [26]. It has also been shown to be
a useful tool for detecting depressive symptoms in vari-
ous adult populations [27-32]. Out of the whole study
population, 429 (15%) subjects with a BDI score ≥10
were identified. In order to examine the effect of the
subtype of DS, we used a summary score of melancholic
symptoms in the BDI based on the DSM-IV- defined cri-
teria for melancholic depression (sadness, past failure,
loss of pleasure, guilty feelings, punishment feelings, loss
of interest, irritability, change of sleeping and appetite)
in dividing the participants with increased DS into mel-
ancholic and non-melancholic depressive symptom
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useful in several previous studies. The subjects were de-
fined to have DS with melancholic characteristics when
the number of melancholic symptoms exceeded the
number of non-melancholic symptoms [29,33-36]. When
using this method the subject had to score 2 or 3 points
in each chosen item in order to have a positive item (a
melancholic or a non-melancholic item).
Laboratory analysis
The study methods followed the World Health
Organization MONICA protocol [37]. After an over-
night fast, blood samples were drawn for basic biochem-
ical measurements, including serum vitamin B12. The
serum and plasma were separated within one hour by
centrifugation at room temperature. The samples were
then aliquoted into storage tubes and stored at a mini-
mum of −20°C. The samples were later transported fro-
zen to the National Institute for Health and Welfare and
stored at −70°C until analyzed at the laboratory of the
Disease Risk Unit.
Serum vitamin B12 was measured with an Architect
ci82000 analyzer (Abbott Laboratories, Abbott Park, IL)
using the Chemiluminescent Microparticle Immuno Assay
(CMIA). The reference range was 138–652 pmol/L for the
normal serum vitamin B12 level. The interassay coefficients
of variation (CV) of B12 vitamin were 6.2% and 5.0% at the
levels of 150 pmol/L and 380 pmol/L, respectively.
Other measurements
Height was measured to the nearest 0.1 cm, and weight
was measured in light clothing to the nearest 0.1 kg. The
body mass index (BMI) was calculated as weight (kg)
divided by the square of height (m). Waist circumference
was measured midway between the lowest rib margin
and the iliac crest. Education was assessed according to
years of education. The participants reported their mari-
tal status, and were categorized as married, single, sepa-
rated or widowed. Employment status was inquired,
and the number of employed participants was count-
ed. Current smoking and alcohol consumption were
assessed with self-administered questionnaires, and di-
chotomized (no or yes). Leisure- time physical activity
(LTPA) was assessed with the question: “How much
physical activity do you practice during leisure- time?”
Response categories were: In my leisure- time I 1) read,
watch television and do things that do not require phys-
ical activity; 2) walk, ride a bicycle or exercise in other
ways requiring physical activity for at least four hours a
week; 3) have physical activities to maintain my condi-
tion such as jogging, cross-country skiing, aerobics,
swimming or ball games at least three hours a week; and
4) practice regularly for competitions in running, cross-
country skiing, orienteering, ball games, or other heavyphysical exercise several times a week. The intensity of
LTPA was classified as low (category 1), moderate (cat-
egory 2) or high (categories 3 and 4) [31]. A chronic dis-
eases sum index was based on the question “Have you
had any of the following diseases that have been diag-
nosed or treated by a doctor in the last 12 months?” The
diseases included elevated blood pressure, heart failure,
angina pectoris/other cardiovascular event, diabetes,
cancer, bronchial asthma/emphysema and rheumatoid
arthritis/other arthropathy/spinal diseases. The chronic
diseases sum index ranged from 0 to 7 [32]. The use of
antidepressive medications was also recorded.
Statistical analysis
The data are presented as means with standard devia-
tions or counts with percentages. Groups were statisti-
cally compared using the t-test, permutation test or chi-
squared test, as appropriate. The statistical significance
between groups was B12 level evaluated by bootstrap
type analysis of covariance (ANCOVA) with appropriate
contrast Multinomial logistic regression was used to
analyze the relative risk ratios (RRR) and their 95% con-
fidence intervals (95% CI) for the presence of non-
melancholic and melancholic DS with appropriate con-
trasts. Adjusted continuous relationship between vitamin
B12 levels and BDI score was analyzed using regression
analysis (with bootstrap based standard error), squared
term of the BDI score was added to an equation.
The multinomial (polytomous) logistic regression
model is an extension of the binomial logistic regression
model and is used when the dependent variable has
more than two nominal (unordered) categories.
Results
The study population (N = 2806) included 429 subjects
(15%) with a BDI score ≥10. Table 1 presents the
sociodemographic characteristics of the two subgroups
with BDI scores <10 or ≥10. Participants with elevated
DS were more likely to be female or older, and to have a
higher BMI, be less educated, unmarried or unemployed.
They also used less alcohol and were less physically ac-
tive than their non-depressed counterparts. Subjects
with increased DS had a higher chronic diseases sum
index, and more often used antidepressive medication.
Vitamin B12 levels differed between males and females
(serum vitamin B12 343 ± 168 pmol/L for females and
312 ± 171 pmol/L for males; p < 0.001). In order to fur-
ther examine the vitamin B12 levels in subjects with de-
pressive symptoms they were subdivided into groups
with predominantly melancholic (N = 138) and non-
melancholic DS (N = 291). The mean vitamin B12 level
was 331±176 pmol/L in those without DS while the sub-
jects with non-melancholic DS had a mean vitamin B12
level of 324 ± 135 pmol/L, and those with melancholic
Table 1 Demographic and clinical data at baseline according to depressive symptom status
Depressive symptoms status P-value
BDI score <10 BDI score ≥10
N = 2377 N = 429
Female, n (%) 1215 (51) 263 (61) <0.001
Age, years, mean (SD) 59 (8) 61 (9) <0.001
Body mass index (kg/m2), mean (SD) 27.3 (4.7) 28.6 (5.6) <0.001
Education years, mean (SD) 11 (8.14) 10 (8.13) <0.001
Marital status, n (%) <0.001
Married 1842 (78) 286 (67)
Single 181 (8) 47 (11)
Separated 215 (9) 61 (14)
Widowed 130 (5) 33 (8)
Employed, n (%) 1229 (52) 113 (26) <0.001
Current smoker, n (%) 508 (21) 111 (26) 0.038
Using alcohol, n (%) 1465 (62) 225 (52) <0.001
Leisure time physical activity, n (%) <0.001
Low 375 (16) 141 (35)
Moderate 1391 (60) 218 (54)
High 561 (24) 46 (11)
Chronic diseases sum index (0–7), mean (SD) 0.60 (1.06) 1.12 (1.30) <0.001
Use of antidepressive medication, n (%) 71 (3) 77 (18) <0.001
Abbreviations. BDI-score ≥10 includes 291 subjects with non-melancholic DS and 138 subjects with melancholic DS.
BDI = Beck Depression Inventory.
DS = depressive symptoms.
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pmol/L (p < 0.001 after adjusted for age, sex, use of
antidepressive medication and chronic diseases sum
index) (Figure 1A). The adjusted difference of vitamin B12
levels between the non-melancholic and the melancholicFigure 1 The association of vitamin B12 levels with depressive and no
symptoms based to BDI scores. A: The association of vitamin B12 levels w
the non-depressive symptoms. B: The association of vitamin B12 levels with
symptoms according to the BDI-scores. C: Non-linear quadric model of the
use of antidepressive medication and chronic diseases. The gray band give
non-melancholic depressive symptoms; MDS, melancholic depressive sympgroup was 33 pmol/L (95%CI 8 to 57, p = 0.008). No dif-
ference was found between those without DS and the
non-melancholic group (Figure 1A). The vitamin B12
levels were significantly lower in the sub-group of melan-
cholic depressive symptoms scoring 10–14 in the BDI.n-depressive symptoms, and with the severity of depressive
ith the non-melancholic or the melancholic depressive symptoms and
severity of the non-melancholic and the melancholic depressive
vitamin B12 levels versus BDI score. Model adjusted using age, sex,
s the 95% confidence intervals. BDI, Beck Depression Inventory; NmDS,
toms.
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melancholic and melancholic depressive symptoms when
subdivided according to the BDI-scores is presented
in Figure 1B.
Figure 1C shows adjusted continuous relationship be-
tween vitamin B12 levels and BDI score.
In the multinomial regression analysis there was an in-
dependent linearly inverse association between the vita-
min B12 tertiles and melancholic depressive symptoms:
the relative risk ratio (RRR) was 2.75 (95% CI 1.66 to
4.56, p for linearity <0.001) in the lowest vitamin B12
level tertile as compared to the highest when those with-
out DS formed the reference group (Table 2). There was
no association between B12 vitamin tertiles and non-
melancholic DS, since the RRR for the lowest vitamin
B12 level tertile versus the highest was 1.20 (95% CI 0.86
to 1.66, p for linearity 0.28) (Table 2).
Discussion
The novel finding in our population-based study, con-
trolled for multiple potential confounders, was that vita-
min B12 levels showed an independent linearly inverseTable 2 Relative risk ratios and their 95% confidence interval
having non-melancholic or melancholic depressive symptoms
Variables NmDS versus BDI < 10 RRR (95% C
Vitamin B12 tertiles*
I 1 (reference)
II 1.01 (0.72 to 1.41)
III 1.20 (0.86 to 1.66)
Male sex 0.59 (0.44 to 0.79)
Age 1.02 (1.00 to 1.04)
BMI 1.02 (1.00 to 1.05)
Smoking 1.23 (0.88 to 1.71)
Using alcohol 1.09 (0.81 to 1.45)
LTPA
I 1 (reference)
II 0.50 (0.37 to 0.68)
III 0.24 (0.15 to 0.39)
Years of education 0.98 (0.94 to 1.02)
Living alone 1.29 (0.95 to 1.75)
Energy intake 1.00 (1.00 to 1.00)
Use of antidepressive medication 5.51 (3.55 to 8.54)
Chronic diseases sum index 1.41 (1.26 to 1.59)
* Gender specific tertiles: Male I > 340 pmol/L, II = 255–340 pmol/L, III < 255 pmol/L;
Female I > 380 pmol/L, II = 280–379 pmol/L, III = <280 pmol/L.
# P for linearity.
RRR = relative risk ratio.
BDI = Beck Depression Inventory.
NmDS = non-melancholic depressive symptoms.
MDS =melancholic depressive symptoms.
BMI = body mass index.
LTPA = leisure-time physical activity.association with the risk of melancholic DS but not with
non-melancholic DS. This result is in line with the
monoamine hypothesis of depressive disorders connecting
a low vitamin B12 level with diminished synthesis of sero-
tonin and other monoamines [4]. In our study we ob-
served an approximately three-fold increased RRR for
melancholic DS in the lowest vitamin B12 tertile. Thus, the
risk is very much in the same range as the results from a
recent study in which vitamin B12 deficiency appeared to
be associated with the occurrence of DS (OR = 2.68) [18].
Two earlier studies reported similar, but somewhat lower
risk levels (OR 2.05 and 1.64, respectively) [15,16]. Previ-
ously we have reported an association between low folate
intake and increasing risk of melancholic DS in this mater-
ial [36]. Homocysteine was not determined in this study.
All the previous studies showing positive relationships
between vitamin B12 levels and DS or depressive disor-
ders have been conducted among older populations
[15-18]. On the other hand, most previous population-
based studies not showing an association between vita-
min B12 levels and depressive disorders or DS have been
conducted on younger populations than that in ours (95% CI) from multinomial regression analysis for
I) P-value MDS versus BDI < 10 RRR (95% CI) P-value
0.28# 1 (reference) <0.001#
1.90 (1.21 to 3.22)
2.75 (1.66 to 4.56)
<0.001 0.82 (0.54 to 1.23) 0.34
0.041 1.02 (1.00 to 1.05) 0.091
0.11 0.98 (0.94 to 1.02) 0.32
0.23 1.41 (0.91 to 2.20) 0.13
0.59 0.84 (0.56 to 1.26) 0.39
<0.001# 0.006#
1 (reference)
0.42 (0.27 to 0.64)
0.43 (0.24 to 0.76)
0.24 1.00 (0.95 to 1.06) 0.99
0.10 1.93 (1.30 to 2.88) 0.001
0.90 1.00 (1.00 to 1.00) 0.74
<0.001 9.45 (5.63 to 15.86) <0.001
<0.001 1.21 (1.02 to 1.45) 0.031
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Australian study that failed to detect this association
among older populations [19,22]. These partly inconsist-
ent results may suggest that the age of the study popula-
tion is important although methodological differences in
subject selection and in the measurement methods of
depressive symptoms or depression, or in the B12 status,
may also contribute. The distribution of depressive sub-
types may also be important as in our study vitamin B12
levels were lower in the melancholic sub-group. In
addition, the severity of DS is also relevant as the differ-
ence was significant only in the sub-group of mild to
moderate depression i.e. 10–14 points in the BDI. The
cut-off points for BDI tertiles were selected according to
previous studies suggesting BDI-score of 10 [25,26] or
14 as proper cut of values [38,39]. Statistical reasons,
such as a low number of subjects, or a large variety of
vitamin B12 levels in the sub-group having BDI-scores
≥15 may have affected the significance of the result.
These previous results suggest that the elderly may be
more vulnerable to low vitamin B12 levels. One plausible
explanation for these findings is that vitamin B12 defi-
ciency is more common in the aged. Its prevalence was
12% in the Finnish population (aged 65–100 years) com-
pared to the finding that 5% of Canadians (age 6–
79 years) were vitamin B12 deficient [40,41]. Lifestyle fac-
tors such as smoking, alcohol consumption and a vege-
tarian diet have been linked with anincreased risk of
vitamin B12 deficiency in younger adults, [42,43] but no
such association was recorded in an aged Finnish popu-
lation [40]. No specific risk group for lower vitamin B12
levels could be defined among the aged [40]. It may also
be possible that the brain effects of low vitamin B12 do
not manifest until much later in life.
The strengths of our study include a large population-
based sample containing middle-aged and elderly sub-
jects with a substantial prevalence of DS. The study
population was also geographically representative, cover-
ing both urban and rural districts in three study areas.
In addition, the study data were comprehensively exam-
ined, and we used a WHO-based study methodology
[37]. The BDI with a cut-off score of 10 points has also
been shown to be a useful instrument for detecting DS
in various adult populations [27-32].
The available evidence suggest some clinical utility and
some validity for the concept of melancholic features [44].
Depression with melancholic or non-melancholic features
can be established by using diagnostic interviews [45,46].
Instead,we used a summary score of melancholic symp-
toms in the BDI based on the DSM-IV- defined criteria
for melancholic depression in order to examine the effect
of the subtype of DS [33]. The way of dividing the DS into
melancholic or non-melancholic DS has been applied in
several previous studies as well [29,34-36].Unfortunately, we were not able to present sensitivity
analysis due to a dicotomous, and not a continuous
method established in dividing DS into melancholic and
non-melancholic DS. Factor analysis was not used be-
cause symtom composition of the resultant factors may
be dependant of the types of samples being studied [33].
Furthermore, due to population-based design of the
study the amount of subjects having lower scores in the
BDI was high.
However, the criteria that guided the choice for melan-
cholic DS need to be discussed more thoroughly. The
chosen melancholic symptoms in the BDI are based on
the DSM-IV- defined criteria for melancholic depression
[47]. Although e.g. irritability can occur in the non-
demented and demented older populations it may be
quite near to agitation which is one the criteria for mel-
ancholic depression in DSM-IV [47,48]. The fatique and
somatic factor symptoms, including irritability, may be
major features of major and in particular of melancholic
depression [49]. Irritability may be a symptom of mixed
depression as well [50]. In addition, 11-21% of persons
in Finland have DS assessed according to the BDI with
the same, a rather low cut-off score of 10 points, which
is in line with the prevalence of 15% shown in the
present study [29,51].
In addition, as the study population was in advanced
middle age, the generalizability of the results to younger
age groups may be limited. Furthermore, due to the
cross-sectional study design, we cannot make inferences
of causality. However, cross-sectional studies can pro-
duce new associations or hypotheses that can be futher
studied in observational settings.
Conclusions
In our study we observed that a higher risk of melan-
cholic depressive symptoms was associated with lower
vitamin B12 levels. Our findings suggest that vitamin B12
may contribute to the pathogenesis of DS, although fur-
ther studies are needed to evaluate the possible associa-
tions between DS and vitamin B12 levels among
populations with different ages and depressive subtypes.
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